Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its recombinant hexavalent norovirus vaccine (Pichia pastoris). The vaccine is designed to prevent acute gastroenteritis caused by genotype infections included in the vaccine.
Norovirus: A Global Health Concern
Norovirus is recognized as one of the primary pathogens causing outbreaks and epidemics of acute gastroenteritis across all age groups worldwide. The impact of norovirus is significant, with outbreaks leading to substantial health and economic burdens. Currently, there are no symptomatic treatment drugs or preventive vaccine products approved for marketing globally.
Kanghua Bio’s Innovative Vaccine Approach
Kanghua Bio’s product stands out as an innovative vaccine based on virus-like particles (VLPs) constructed using genetic engineering technology. This approach theoretically has the potential to prevent over 90% of norovirus infections and the acute gastroenteritis they cause. The approval of the clinical trial marks a significant step forward in the development of a vaccine that could have a profound impact on public health worldwide.-Fineline Info & Tech
